Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAL-222 in Myopic Chorioretinal Atrophy (PAMyCA)
jRCT2043220105Phase 1Active, not recruiting
- Sponsor
- Teijin Regenet
- Start
- Feb 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PAL-222 in degenerative myopia and Pathologic Myopia (PM), sponsored by Teijin Regenet. Primary endpoint: Change in chorioretinal atrophic area. Started Feb 2023; status: active, not recruiting.
02
Drugs
PAL-222
03
Conditions
degenerative myopiaPathologic Myopia (PM)
Beyond the preview
Go deeper on jRCT2043220105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043220105.